Introduction {#s1}
============

Poor medication adherence to long-term pharmacological therapies is a public health concern that affects mostly patients with non-communicable chronic diseases ([@B1], [@B2]) such as type 2 diabetes mellitus and ischemic heart disease (IHD), both global epidemics of the twenty-first century for men and women ([@B3]--[@B5]). Among diabetic patients, the non-adherence to glucose-lowering drugs results in a suboptimal glycemic control with higher risk of diabetes-related microvascular complications ([@B6], [@B7]). Moreover, diabetic patients should be treated with cardiovascular drugs to prevent macrovascular complications including IHD ([@B8]--[@B10]). Sex differences in the cardiovascular consequences of diabetes exist and should be specifically addressed in the management of diabetic patients ([@B11]--[@B13]).

Multiple variables affecting physicians and patients contribute to medication non-adherence, which in turn negatively affects treatment outcomes and causes psychosocial complications, reduces patients\' quality of life, and wastes health care resources ([@B14]--[@B16]). The World Health Organization suggests that improving adherence requires a multidimensional approach (i.e., social and economic factors, health-care team and system-related factors, condition-related factors, therapy-related factors, and patient-related factors), highlighting that psycho-socio-cultural factors need to be considered as contributors ([@B17]).

Even though sex- (i.e., biological factors) and gender- (i.e., psycho-socio-cultural factors) differences play a very important role in influencing clinical outcomes, both aspects are generally overlooked and under-reported ([@B18], [@B19]). While biological sex variables refer to objectively measurable organs, hormones, genes, anatomy, and physiology, gender represents a social construct that is linked to economic and social status ([@B20]). It has several dimensions, including gender identity (how individuals perceive and present themselves), gender norms (behavioral expectations based on individual sex including role in the family, in the workplace, in society, etc.), and gender relations (emotional and economic relations between individuals) ([@B21]). As sex and gender are not independent, exclusively assessing one or the other fails to account for identified variations in health ([@B22], [@B23]). Specifically, their role and interaction as determinants of medication adherence are still not fully understood. Moreover, the complexity of gender and the lack of a validated standardized measurement, with the exception of the GENESIS-PRAXY gender score ([@B23], [@B24]), both contribute to the paucity of data available including medication adherence.

Based on a prospective cohort of patients hospitalized for IHD events, with the unique systematic collection of gender-related variables, we explored the factors associated with pre-admission medication adherence and whether any sex differences exist in the effect of diabetes and gender-related variables on pre-admission medication adherence.

Materials and Methods {#s2}
=====================

Data for the present analysis come from the "Endocrine Vascular disease Approach" (EVA) project (ClinicalTrials.gov Identifier: NCT02737982), an ongoing prospective observational study aiming to explore sex and gender differences in the interaction of platelet function, sex hormone balance, and coronary microvascular dysfunction in IHD ([@B25]). In brief, EVA is a registry of men and women, aged 18 and older, who were referred to the cardiac catheterization laboratory to undergo coronary angiography and/or percutaneous coronary intervention for suspected IHD, Patients with active cancer (i.e., currently treated with chemotherapy or at ≤5 years from diagnosis), current pregnancy, previous coronary artery bypass graft, documented moderate-severe valvular heart disease, and prosthetic valve carriers were excluded. Therefore, the EVA study population includes patients with stable coronary artery disease, patients with non-ST elevation acute coronary syndrome and patients with ST elevation myocardial infarction. The recruitment phase is still ongoing.

The study was conducted in full conformance with the principles of the Declaration of Helsinki, the laws and regulations of Italy, or whichever afforded greater protection to the individual. The study obtained the required authorization by the local Ethics Committee of Policlinico Umberto I, Sapienza University of Rome (reference 3786, 24/09/2015). Written informed consent has been obtained from all patients.

Among the study population, we selected baseline data from patients recruited until August 2018.

Baseline Clinical Characteristics and Gender-Related Factors
------------------------------------------------------------

We selected patients with complete information at baseline regarding: (1) anthropometric data (including height, weight, blood pressure, heart rate); (2) independent functional status assessed by the Duke Activity Status Index ([@B26]); (3) presence of diabetes; (4) cardiovascular risk factors including family history of cardiovascular disease; hypertension; dyslipidemia; chronic kidney disease; previous cardiovascular events including prior MI and stent implantation. Patients\' baseline characteristics were selected from a combination of medical record abstraction and standardized in-person interviews administrated by trained personnel.

According to the definition of gender components designed by the Women\'s Health Research Network ([@B21]), we collected the following gender-related factors: (1) gender role: household\'s primary earner status and employment status; (2) gender relations: marital status (i.e., married/living with partner vs. others); (3) gender identity: Bem Sex Role Inventory (BSRI) masculine and feminine ([@B27]), and level of stress (defined through the 10-item perceived stress scale) ([@B28]); (4) institutionalized gender: low socioeconomic status \[defined as low education level (i.e., less than secondary school) and/or low household income (i.e., \<1,000 Euro per month)\]. Furthermore, we considered the following as risk-taking behaviors: alcohol consumption (i.e., more than 2 units per day for women and 3 units per day for men), physical inactivity (defined as no recreational activity or less than once per week), and smoking habits (current smoker). All the gender-related variables were collected through self-reported questionnaires.

Pre-admission Medication Adherence Assessment
---------------------------------------------

Pre-admission medication adherence has been assessed using a self-administrated questionnaire at the baseline visit. A simple self-reported measure of medication adherence, which has been shown to be predictive of blood pressure control ([@B29]), was used to measure medication-taking behavior (i.e., trouble in remembering to take medication, spontaneous interruption due to personal judgment) among our hospitalized patients undergoing coronary angiography for suspected IHD. Polypharmacy was defined as more than 5 drugs assumed daily by the patient as previously reported ([@B30]). Information concerning the class of drugs taken by the patient include: antithrombotic agents (i.e., anticoagulants and antiplatelet drugs), b-adrenergic receptor blockers (b-blockers), hydroxylmethylglutaryl-coenzyme A reductase inhibitors (statins), angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, oral glucose lowering drugs, or subcutaneous insulin.

Statistical Analysis
--------------------

After verification of non-normality, continuous variables were reported as median and interquartile range (IQR). Differences between the groups (low-adherent vs. medium-high adherent) were established, according to non-normal distribution, with a non-parametric test, the Mann-Whitney *U*-test. Categorical variables were reported as counts and percentages, and differences between groups (low-adherent vs. medium-high adherent) were evaluated with chi-square test or Fisher\'s Exact test when appropriate (cell count \<5).

A logistic regression model was computed to identify the predictors of medium-high adherence. Both in the overall model, as well as in the sex-stratified analysis, variables which significantly differed at baseline with a *p*-value \< 0.10 were identified to be included in a univariate analysis. All variables associated with adherence for \<10% (*p* \< 0.10) at univariate analysis, were included in the final multivariate model. A two-sided *p*-value \< 0.05 was considered as statistically significant. All analyses were performed using SPSS v. 25.0 (IBM, NY, USA).

Results {#s3}
=======

Among the EVA cohort, 280 (median \[IQR\] age 70 \[63--76\] years; 35% women) patients hospitalized for IHD were analyzed. Preadmission low-adherence was reported in 24% (*n* = 67) of patients, regardless of sex.

Clinical characteristics according to adherence are reported in [Table 1](#T1){ref-type="table"}. Low-adherent patients were more likely to be diabetic as compared with adherent patients. No statistically significant difference in pre-admission medication adherence was found between women and men with or without prior history of IHD (74 vs. 77%, respectively). No differences in age, sex, blood pressure, body mass index, main cardiovascular co-morbidities, type of drugs, and polypharmacy were observed between medium-high adherent and low-adherent subjects. The distribution of gender-related factors according to pre-admission medication adherence status is shown in [Table 2](#T2){ref-type="table"}. The only gender-related factor statistically more prevalent in low-adherent patients was to be employed. Other psycho-socio-cultural factors were similar among the 2 groups.

###### 

Baseline clinical characteristics of EVA patients according to pre-admission medication adherence.

                                  **Low adherence (*n* = 67)**   **Medium-high adherence (*n* = 213)**   ***p***
  ------------------------------- ------------------------------ --------------------------------------- ---------
  Age, *years* median \[IQR\]     68 \[61--78\]                  71 \[63--76\]                           0.447
  Women, n (%)                    24 (35.8)                      74 (34.7)                               0.872
  BMI, *kg/m^2^* median \[IQR\]   27.0 \[24.8--30.0\]            26.5 \[24.2--29.5\]                     0.447
  SBP, *mmHg* median \[IQR\]      130 \[120--150\]               130 \[120--140\]                        0.104
  DBP, *mmHg* median \[IQR\]      80 \[70--85\]                  80 \[70--80\]                           0.537
  HR, *bpm* median \[IQR\]        70 \[62--80\]                  70 \[60--76\]                           0.239
  Hypertension                    57 (86.4)                      181 (85.0)                              0.781
  Dyslipidemia                    41 (61.2)                      122 (57.3)                              0.571
  Type 2 diabetes                 27 (40.3)                      58 (27.2)                               0.042
  Active Smoke                    15 (22.7)                      49 (23.2)                               0.934
  Alcohol Abuse                   11 (16.4)                      36 (17.7)                               0.805
  Physical inactivity             57 (85.1)                      167 (78.4)                              0.234
  History of CAD                  28 (41.8)                      79 (37.1)                               0.490
  Vascular disease                21 (31.8)                      58 (27.2)                               0.470
  Stroke/TIA                      7 (10.6)                       24 (11.3)                               0.881
  CKD                             17 (26.2)                      53 (25.7)                               0.945
  Polypharmacy                    38 (56.7)                      106 (49.8)                              0.321
  DASI, median \[IQR\]            27.0 \[19.0--42.7\]            32.2 \[19.0--49.8\]                     0.153
  **Therapy pre-admission**                                                                              
  \- Glucose lowering drugs       17 (25.4)                      41 (19.2)                               0.281
  \- Insulin                      7 (10.4)                       12 (5.6)                                0.172
  \- Statins                      32 (47.8)                      110 (51.6)                              0.579
  \- Antiplatelets                43 (64.2)                      135 (63.4)                              0.906
  \- Anticoagulants               8 (11.9)                       19 (8.9)                                0.465
  \- Beta-Blockers                30 (44.8)                      96 (45.1)                               0.966
  \- ACEi                         19 (28.4)                      57 (26.8)                               0.798
  \- ARBs                         18 (26.9)                      76 (35.7)                               0.183

*Data are presented as number of patients (%) unless otherwise specified*.

*IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; ACEi, Angiotensin converting enzyme inhibitors; ARBs, Angiotensin II receptor blockers. When missing data are more than 10%, they are reported in brackets*.

###### 

Gender-related factors of EVA patients according to pre-admission medication adherence.

                                                         **Low adherence (*n* = 67)**   **Medium-High Adherence (*n* = 213)**   ***p***
  ------------------------------------------------------ ------------------------------ --------------------------------------- ---------
  Employed status                                        27 (40.3)                      57 (27.0)                               0.039
  Primary earner[^\#^](#TN2){ref-type="table-fn"}        19 (38.0)                      83 (49.4)                               0.156
  Male BSRI, median \[IQR\]                              5.0 \[4.1--5.6\]               4.7 \[4.1--5.4\]                        0.552
  Female BSRI, median \[IQR\]                            5.8 \[5.2--6.4\]               5.9 \[5.3--6.2\]                        0.991
  High Stress at home[^\#^](#TN2){ref-type="table-fn"}   14 (29.2)                      44 (26.2)                               0.682
  Married/living with partner                            46 (68.7)                      149 (70.0)                              0.840
  Low SES[^\*^](#TN1){ref-type="table-fn"}               36 (53.7)                      96 (45.1)                               0.215

*Data are presented as number of patients (%) unless otherwise specified*.

SES, socioeconomic status; BSRI, Bem Sex Role Inventory;

*SES was defined based on low education level and/or personal income*.

*data available for 215 patients*.

When data were stratified by sex, we observed that low-adherent men were most likely employed yet not primary earners, and with more masculine personality traits ([Table 3](#T3){ref-type="table"}). On the other hand, low-adherent women were most likely diabetic and physically inactive, with no statistical differences in any gender-related factor ([Table 4](#T4){ref-type="table"}). No differences in the types of drugs taken were observed in both sexes.

###### 

Clinical and gender-related factors in men according to pre-admission medication adherence.

                                                         **Low adherence (*n* = 43)**   **Medium-high adherence (*n* = 139)**   ***p***
  ------------------------------------------------------ ------------------------------ --------------------------------------- ---------
  Age, *years* median \[IQR\]                            65 \[60--74\]                  69 \[63--75\]                           0.157
  BMI, *kg/m^2^* median \[IQR\]                          27.5 \[25.3--31.0\]            27.1 \[25.1--29.4\]                     0.576
  SBP, *mmHg* median \[IQR\]                             120 \[110--130\]               120 \[110--130\]                        0.200
  DBP, *mmHg* median \[IQR\]                             80 \[70--85\]                  80 \[70--85\]                           0.973
  HR, *bpm* median \[IQR\]                               70 \[62--78\]                  69 \[60--76\]                           0.279
  Hypertension                                           37 (88.1)                      123 (88.5)                              0.944
  Dyslipidemia                                           27 (62.8)                      85 (61.2)                               0.847
  Type 2 diabetes                                        17 (39.5)                      43 (30.9)                               0.294
  Active Smoke                                           13 (30.2)                      36 (26.1)                               0.593
  Alcohol Abuse                                          10 (23.3)                      32 (24.2)                               0.895
  Physical inactivity                                    33 (76.7)                      104 (74.8)                              0.798
  History of CAD                                         23 (53.5)                      61 (43.9)                               0.270
  Vascular disease                                       13 (31.0)                      43 (30.9)                               0.998
  Stroke/TIA                                             4 (9.5)                        14 (10.1)                               0.917
  CKD                                                    9 (22.0)                       32 (23.7)                               0.816
  Polypharmacy                                           25 (58.1)                      72 (51.8)                               0.466
  DASI, median \[IQR\]                                   8.5 \[3.0--14.0\]              5.0 \[2.0--11.5\]                       0.610
  Employed status                                        25 (58.1)                      46 (33.3)                               0.004
  Primary earner[^\#^](#TN4){ref-type="table-fn"}        18 (54.5)                      77 (73.3)                               0.042
  Male BSRI, median \[IQR\]                              5.2 \[5.0--5.8\]               4.9 \[4.4--5.5\]                        0.059
  Female BSRI, median \[IQR\]                            6.0 \[5.1--6.4\]               5.6 \[5.−6.2\]                          0.581
  High stress at home[^\#^](#TN4){ref-type="table-fn"}   5 (18.8)                       19 (18.4)                               0.969
  Married/living with partner                            33 (76.7)                      109 (78.4)                              0.817
  Low SES[^\*^](#TN3){ref-type="table-fn"}               20 (46.5)                      54 (38.8)                               0.371

*Data are presented as number of patients (%) unless otherwise specified*.

IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; SES socioeconomic status; BSRI, Bem Sex Role Inventory;

*SES was defined based on low education level and/or personal income*.

*data available for 135 men*.

###### 

Clinical and gender-related factors in women according to pre-admission medication adherence.

                                                         **Low adherence (*n* = 24)**   **Medium-high adherence (*n* = 74)**   ***p***
  ------------------------------------------------------ ------------------------------ -------------------------------------- ---------
  Age, years median \[IQR\]                              72 \[64--81\]                  74 \[65--78\]                          0.568
  BMI, kg/m^2^ median \[IQR\]                            26.3 \[24.2--28.8\]            24.9 \[22.2--29.7\]                    0.435
  SBP, mmHg median \[IQR\]                               130 \[125--140\]               130 \[120--140\]                       0.315
  DBP, mmHg median \[IQR\]                               75 \[70--90\]                  70 \[70--80\]                          0.259
  HR, bpm median \[IQR\]                                 72 \[60--80\]                  72 \[65--77\]                          0.526
  Hypertension                                           20 (83.3)                      58 (78.4)                              0.601
  Dyslipidemia                                           14 (58.3)                      37 (50.0)                              0.478
  Type 2 diabetes,                                       10 (41.7)                      15 (20.3)                              0.037
  Active Smoke                                           2 (8.7)                        13 (17.8)                              0.294
  Alcohol Abuse                                          1 (4.2)                        4 (5.6)                                0.781
  Physical inactivity                                    24 (100.0)                     63 (85.1)                              0.045
  History of CAD                                         5 (20.8)                       18 (24.3)                              0.726
  Vascular disease                                       8 (33.3)                       15 (20.3)                              0.189
  Stroke/TIA                                             3 (12.5)                       10 (13.5)                              0.899
  CKD                                                    8 (33.3)                       21 (29.6)                              0.730
  Polypharmacy                                           13 (54.2)                      34 (45.9)                              0.484
  DASI, median \[IQR\]                                   11 \[7--25\]                   10 \[6.8--15\]                         0.114
  Employed status                                        2 (8.3)                        11 (15.1)                              0.401
  Primary earner[^\#^](#TN6){ref-type="table-fn"}        1 (5.9)                        6 (9.5)                                0.637
  Male BSRI, median \[IQR\]                              4.3 \[3.7--4.6\]               4.6 \[4.0--5.4\]                       0.106
  Female BSRI, median \[IQR\]                            5.7 \[5.0--6.8\]               6.0 \[5.6--6.6\]                       0.773
  High stress at home[^\#^](#TN6){ref-type="table-fn"}   8 (50.0)                       25 (38.5)                              0.400
  Married/living with partner                            13 (54.2)                      40 (54.1)                              0.992
  Low SES[^\*^](#TN5){ref-type="table-fn"}               16 (66.7)                      42 (56.8)                              0.391

*Data are presented as number of patients (%) unless otherwise specified*.

IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; TIA, Transient ischemic attack; CKD, chronic kidney disease; DASI, Duke Activity Status Index; SES socioeconomic status; BSRI, Bem Sex Role Inventory;

*SES was defined based on low education level and/or personal income*.

*data available for 80 women*.

Therefore, we explored the determinants of pre-admission adherence: only being employed was independently associated with medication adherence status \[Odds Ratio (OR) 0.55, 95% Confidence Interval (CI) 0.31--0.97, *p* = 0.041\] in our cohort ([Table 5](#T5){ref-type="table"}). However, when we stratified the analysis by sex, only a BSRI masculine (OR 0.59, 95%CI 0.35--0.99, *p* = 0.048) was inversely associated with adherence in men, while only diabetes (OR 0.36; 95%CI 0.13--0.96, *p* = 0.041) in women ([Table 5](#T5){ref-type="table"}).

###### 

Multivariate logistic regression of pre-admission medication adherence in patients admitted for ischemic heart disease.

                        **OR**   **95% CI**   ***p***
  --------------------- -------- ------------ ---------
  **OVERALL**                                 
  Employed status       0.55     0.31--0.97   0.041
  **MALE PATIENTS**                           
  Male BSRI             0.59     0.35--0.99   0.048
  **FEMALE PATIENTS**                         
  Type 2 diabetes       0.36     0.13--0.96   0.041

*OR, Odds Ratio; CI, confidence interval; BSRI, Bem Sex Role Inventory*.

Discussion {#s4}
==========

The main findings of our analysis are that: (i) pre-admission poor adherence was highly prevalent, characterizing more than one fourth of men and women hospitalized for IHD; (ii) diabetes was the only cardiovascular risk factor significantly prevalent in low-adherent patients with IHD before hospitalization; (iii) among the gender-related variables, employed status, as proxy of the gender role, was negatively associated with medication adherence; and (iv) factors related to pre-admission adherence differed between sexes, with diabetes being more relevant for women, while masculine traits of personality were independently associated with low-adherence in men.

Medication low-adherence is a major and costly obstacle in the management of common non-communicable chronic diseases, such as hypertension and diabetes ([@B16], [@B31], [@B32]). The prevalence of medication non-adherence varies tremendously depending on the population studied, the method used for assessment of medication use (e.g., self-report or pharmacy refill data) and the specific medications assessed ([@B15], [@B33]--[@B35]). Moreover, significant sex differences were previously reported in general drug-users in terms of intensity of medication use and compliance to treatment ([@B36]). Interestingly, in our cohort of patients admitted for an IHD event, the pre-admission poor medication adherence was similarly high (25%) among women and men. However, we identified different factors associated to inappropriate drug behavior among sexes that should be considered when targeting obstacles for improving patient adherence to pharmacological treatment.

Diabetes is the only condition that reverses the female advantage in cardiovascular risk ([@B37]). Diabetic women experience worse clinical outcomes compared to age-matched diabetic men, especially in the setting of ischemic heart disease ([@B38]). In our cohort, diabetic women hospitalized for an ischemic coronary event were more likely low-adherent to therapy before admission. Diabetes was found as the only clinical determinant of pre-admission medication adherence in a sex-specific manner, despite the low sample of women enrolled in the present analysis. On the other hand, diabetes loses its explanatory power when gender-related factors are considered in the subgroup of male patients. We provide an example of how controlling and adjusting the analysis for sex can lead to a misinterpretation of data, especially when the women are underrepresented in a study population. Therefore, an analysis disaggregated by sex might inform our better understanding of the outcomes of interest in men and women. In fact, the approach of reporting data disaggregated by sex and a sex-stratified analysis are recommended by the international clinical research stakeholders ([@B39], [@B40]).

The distinction between sex and gender, which is clear and common in the social sciences, has largely been neglected in health science. In truth, sex and gender are often erroneously used and/or measured interchangeably ([@B18]). The integration of sex- and gender-based analysis is a much-needed and, yet, uncommon approach to improving the quality of evidence and guaranteeing the generalizability of findings. However, when considering gender in the evaluation of clinical outcomes, the first hurdle for researchers originates from the apparent lack of standardized methods to measure the complexities of all that gender encompasses. Recently, through a Pan-Canadian collaboration of a multi-disciplinary team of scientists, a comprehensive list of gender-related variables was established and collected in the setting of premature cardiovascular disease ([@B23]). Using the EVA cohort, we could now potentially describe every dimension of gender through a granularity of data which is rarely available. In the analysis adjusted for sex, employment status was the only factor associated to medication adherence: specifically, employed status has a negative influence on adherence to therapy. This difference in adherence between unemployed and employed could be attributed to the busy work schedules of working patients, which could interfere with adequate behaviors of self-care. However, in literature, the link between employed status and medication adherence has been barely explored. Our findings have therefore raised important unexplored questions on the mechanisms explaining the association between gender roles and medication adherence in patients at high cardiovascular risk. Apart from work status, personality traits (considered as expressions of gender identity) seem to play a pivotal role in medication adherence ([@B41], [@B42]). It was reported that some personality traits such as emotional stability, interpersonal orientation, and motivation in goal-directed behavior are associated to medication adherence in individuals with chronic disease ([@B41]). In this light, we observed that beyond clinical characteristics, a higher BSRI masculine score, calculated on personality traits (including risk-taking behavior, independence, competitiveness, strong personality, etc.) can be negatively associated to pre-admission medication adherence in men hospitalized for IHD. This finding may be explained by the tendency of male patients with these personality traits to put high trust in their own ability to manage their health, therefore underestimating the importance of adherence to health providers\' prescriptions ([@B41], [@B43]).

The present analysis has several strengths worth mentioning. We were uniquely positioned to evaluate all 4 dimensions that gender constructs encompass in a "real-world," contemporary cohort of patients with IHD. We also had a granularity in the data exploring gender constructs which is largely uncommon. Finally, as recommended by international societies and funding agencies ([@B39], [@B40]), we could report the data disaggregated by sex.

Limitations
-----------

Some important limitations of the present analysis must be stated. As any observational cohort study, some confounders might not have been assessed and could influence our final multivariate model, as could any missing data points.

Furthermore, the sample size is small, and the EVA study was not specifically designed to test the effect of diabetes on pre-admission medication adherence outcomes. The lack of statistical significance in the effect of sex or gender-related factors may be due to the lack of power to address specific differences. We cannot exclude that, as the sample increases, some relevant differences might emerge. Moreover, the findings refer to a selected cohort of patients at very high cardiovascular risk, hospitalized for an ischemic event, at a single center in Italy, limiting the generalizability of our results. We cannot account for countries with specific differences in psychosocial and cultural factors.

Finally, medication adherence is related to the global patient assumption of drugs pre-admission, yet we cannot describe the nuances of adherence separately for each class of drugs, such as glucose lowering drugs or cardiovascular preventive drugs (i.e., anti-platelets or statins).

Future Directions
-----------------

Overall, the present analysis highlights the importance of considering the different effects of clinical characteristics (e.g., diabetes) and gender-related factors (e.g., personality traits or employment status) among women and men, in order to better identify and target high-risk subgroups of patients. The impact of pre-admission medication adherence on clinical outcomes in IHD patients, including diabetics, is a surprisingly underestimated issue ([@B13]) which requires further investigation ([@B44], [@B45]). Clinicians should consider the use of prior medication adherence as an indicator of future medication-taking behavior.

Future studies---powered and able to apply a gender transformative framework ([@B46]) in the consideration of the specific research questions---are warranted, with the overarching aim to ultimately design effective interventions to promote health and well-being.

New approaches such as big data analysis ([@B47]) across patient data registries across countries could be interesting avenues to explore the impact of gender-related factors as determinants of clinically relevant outcomes on a larger, population-based scale.

Conclusion {#s5}
==========

Poor medication adherence is still a highly prevalent condition in patients at high cardiovascular risk. Medication adherence recognizes disease-centered and patient-centered determinants. Among them, gender-related factors (i.e., personality traits and gender role) and diabetes are associated in a sex-specific manner with pre-admission medication adherence of patients hospitalized for IHD. Future clinical trials should test if sex-specific and gender-sensitive interventions might improve medication adherence in high cardiovascular risk conditions, such as women with diabetes.
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